Other compounds targeting key glycolytic enzymes (such as 2-deoxyglucose and 3-bromopyruvate, which are HK2 inhibitors, and PKM2-IN-1, a PKM2 inhibitor) have shown anti-tumor effects in preclinical models [150]. The gene discussed is PKM; the disease is neoplasm.